Practice Update | Onology

CONTENTS 5

RESEARCH Editor’s picks 6 Consensus conference on de-escalating and 7 Dabrafenib plus trametinib in patients with BRAF(V600)- mutant melanoma brain metastases (COMBI-MB) and trastuzumab in early HER2+ breast cancer 9 Surgical resection vs watchful waiting in low- grade glioma Breast 22 Risks of breast, ovarian, and contralateral breast cancer for BRCA1- and BRCA2-mutation carriers 8 Adjuvant pertuzumab escalating treatments for early-stage breast cancer

Cover 6 Consensus

PracticeUpdate Oncology is published by Elsevier Australia ISSN 2207-869X (Print) ISSN 2207-8703 (Online) Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. SALES Fleur Gill fleur.gill@elsevier.com Linnea Mitchell-Taverner l.mitchell@elsevier.com PRODUCTION Editorial Manager Anne Neilson anne.neilson@elsevier.com Editorial Project Manager Carolyn Ng Designer Jana Sokolovskaja Cover: Dividing breast cancer cell. ABN 70 001 002 357 475 Victoria Avenue Chatswood NSW 2067 Australia Locked Bag 7500 Chatswood DC NSW 2067 EMON071701 PracticeUpdate® is a registered trademark of Elsevier Inc. © 2017 Elsevier Inc. All rights reserved. ABOUT PracticeUpdate Oncology provides coverage of key research from leading international conferences, and a collection of top journal articles and accompanying expert commentaries in a convenient print periodical. These and more are also available online at www. practiceupdate.com PracticeUpdate and PracticeUpdate Oncology are commercially supported by advertising, sponsorship, and educational grants. Individual access to PracticeUpdate.com is free. Premium content is available to any user who registers with the site. While PracticeUpdate is a commercially-sponsored product, it maintains the highest level of academic rigour, objectivity, and fair balance associated with all Elsevier products. No editorial content is influenced in any way by commercial sponsors or content contributors. DISCLAIMER PracticeUpdate Oncology has been developed for specialist medical professionals. The ideas and opinions expressed in this publication do not necessarily reflect those of the Publisher. Elsevier will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Please consult the full current Product Information before prescribing any medication mentioned in this publication. PracticeUpdate is guided by a world-renowned Editorial and Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise. Editor-in-Chief Lee Schwartzberg MD FACP Associate Editors Isabel Cunningham MD Axel Grothey MD Advisory Board Kimberly Blackwell MD, Roxana Dronca MD, Wilfried Eberhardt MD, Rafael Fonseca MD, Andre Goy MD, Annette Hasenburg Prof Dr med, David Henry MD, Eric Jonasch MD, Jeffrey Kirshner MD, FACP, Ruben Niesvizky MD, Howard Scher MD, David Straus MD, Roger Stupp MD Editorial Contributors Brandt Esplin MD PhD, Jeremy Jones MD, Jarushka Naidoo MD, Moshe Ornstein MD, Erin Schenk MD PhD

Conference 10 American Society of Clinical conference on de-escalating and escalating treatments for early-stage breast cancer Oncology 2017 Annual Meeting

10 Practice changers in advanced prostate cancer: STAMPEDE, LATITUDE vis-à-vis CHAARTED 11 Practice changers in breast cancer 14 Ten practice changes I will make after attending ASCO 2017 16 New standard of care for low risk stage 3 colorectal cancer? 17 Extent of lymph node dissection in prostatectomy: an update 18 Significant updates in glioblastoma 20 Novel treatment options for RCC: a review 20 Practice changers in myeloma

Melanoma 23 Adoptive transfer of tumor-infiltrating

lymphocytes for metastatic uveal melanoma

Colon & Rectum 24 Clinical implications of monitoring circulating

Features 28 My Approach Medullary

tumor DNA in patients with colorectal cancer

24 First-line chemotherapy combined with cetuximab or bevacizumab for KRAS wild-type advanced or metastatic colorectal cancer Genitourinary 26 Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer 27 Similar oncological outcomes with partial and radical nephrectomy in RCC ≥4 cm

thyroid cancer and its primary treatment 30 Q & A Critical issues in thoracic oncology

VOL. 1 • NO. 2 • 2017